Studies genetic markers linked to liver harm from asparaginase in leukemia
Tests saliva genetic markers in adults newly diagnosed with acute lymphoblastic leukemia.
Key facts
- Who runs it
- University of Southern California
- Where
- Los Angeles, United StatesSee the 2 sites
- Trial code
- Registry title
- Pharmacogenomics of Asparaginase Induced Hepatotoxicity
- Status
- Recruiting
- People taking part
- 500 people, planned
- Started
- 22 May 2018
- Expected to end
- 31 Dec 2027
- Type of study
- Observational
- Treatments tested
- Biospecimen Collection
- Record updated
- 1 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed acute lymphoblastic leukemia (ALL) who are getting asparaginase as part of their main treatment. It studies genes that may predict liver damage from asparaginase.
- Age
- 18 years and older
- Sex
- All sexes can join.
- Disease stage
- Newly diagnosed acute lymphoblastic leukemia (ALL).
- Earlier treatment
- No earlier treatment for ALL. Asparaginase must be part of the main treatment plan. For the retrospective group: asparaginase received between 2012 and 2017, and a current patient of the University of Southern California (USC).
Main reasons for not taking part
- People who cannot give informed consent
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Newly diagnosed with acute lymphoblastic leukemia (ALL) - no prior treatment for ALL
- Receiving asparaginase as part of the primary treatment regimen
- Ability to understand and the willingness to sign a written informed consent
- For retrospective recruitment, those who have received asparaginase between 2012 and 2017; and are current patients of University of Southern California (USC)
Who cannot take part
- Patients who are unable to give informed consent
Where in United States
- Los Angeles General Medical CenterLos Angeles, United StatesContact: Houda Alachkar, PhDTaking people
- USC / Norris Comprehensive Cancer CenterLos Angeles, United StatesContact: Houda Alachkar, PhDTaking people
About the trial
What the trial wants to find out
This pilot trial studies the impact of genetic information on developing liver damage caused by asparaginase in participants with newly diagnosed acute lymphoblastic leukemia. Testing saliva samples may help doctors find certain genetic markers that may predict whether participants will tolerate asparaginase, which is given as part of clinical care for acute lymphoblastic leukemia.
The group in the trial
- Biospecimen Collection
Buccal swabs of prospective participants' saliva will be collected when participant achieves complete remission (during regular clinical visit) from their asparaginase treatment.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pharmacogenomics of Age-Specific, Asparaginase-Induced Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia
- Plain-language title
- Studies genetic markers linked to liver harm from asparaginase in leukemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 1 June 2026